XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1

Shareholders' Equity - (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Dec. 31, 2023	Sep. 19, 2022
Immunovant, Inc. [Member]
Shareholders' Equity [Abstract]
Ownership percentage			55.00%
Common Stock [Member] | Investor [Member]
Shareholders' Equity [Abstract]
Sale of common shares (in shares)		19,600,685
Purchase price (in dollars per share)		$ 10.21
Net proceeds from sale of common stock		$ 199.8
Underwritten Public Offering [Member] | Immunovant, Inc. [Member]
Shareholders' Equity [Abstract]
Net proceeds of common stock	$ 466.7
Underwritten Public Offering [Member] | Common Stock [Member] | Immunovant, Inc. [Member]
Shareholders' Equity [Abstract]
Sale of common shares (in shares)	8,475,500
Roivant participation of Immunovant Stock offering [Member] | Common Stock [Member]
Shareholders' Equity [Abstract]
Purchase price (in dollars per share)	$ 38
Common shares purchased by RSL (in shares)	1,526,316
Option purchase additional shares of common stock (in shares)	1,105,500
Private Placement [Member] | Common Stock [Member] | Immunovant, Inc. [Member]
Shareholders' Equity [Abstract]
Purchase price (in dollars per share)	$ 38
Common shares purchased by RSL (in shares)	4,473,684
Cowen [Member] | At-the-Market Equity Offering Program[Member]
Shareholders' Equity [Abstract]
Common shares aggregate offering price authorized				$ 400.0
Common shares aggregate offering price authorized, remaining capacity available			$ 400.0

X

- Definition

The common shares aggregate offering price authorized remaining capacity to issue under equity offering program.

+ References

No definition available.

+ Details

Name:	roiv_CommonSharesAggregateOfferingPriceAuthorizedRemainingCapacityAvailable
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The common shares aggregate offering price authorized to issue under equity offering program.

+ References

No definition available.

+ Details

Name:	roiv_CommonSharesOfferingPriceAuthorized
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The estimated net cash inflow from the additional capital contribution to the entity.

+ References

No definition available.

+ Details

Name:	roiv_EstimatedNetProceedsFromIssuanceOfCommonStock
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The net cash inflow from the additional capital contribution to the entity.

+ References

No definition available.

+ Details

Name:	roiv_NetProceedsFromIssuanceOfCommonStock
Namespace Prefix:	roiv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of additional shares of common stock option to purchase.

+ References

No definition available.

+ Details

Name:	roiv_OptionToPurchaseAdditionalSharesOfCommonStock
Namespace Prefix:	roiv_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percentage of ownership interest.

+ References

No definition available.

+ Details

Name:	roiv_OwnershipPercentage
Namespace Prefix:	roiv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of new stock purchased during the period.

+ References

No definition available.

+ Details

Name:	roiv_StockPurchasedDuringPeriodByEntityShares
Namespace Prefix:	roiv_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_ImmunovantIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_TitleOfIndividualAxis=us-gaap_InvestorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=roiv_RoivantParticipationOfImmunovantStockOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=roiv_CowenAndCompanyLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=roiv_EquityOfferingsAtTheMarketMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: